D
David Laplaud
Researcher at French Institute of Health and Medical Research
Publications - 94
Citations - 3618
David Laplaud is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 18, co-authored 56 publications receiving 2396 citations. Previous affiliations of David Laplaud include University of Nantes & Centre Hospitalier Universitaire de Nantes.
Papers
More filters
Journal ArticleDOI
Microglial control of astrocytes in response to microbial metabolites
Veit Rothhammer,Davis M. Borucki,Emily C. Tjon,Maisa C. Takenaka,Chun-Cheih Chao,Alberto Ardura-Fabregat,Kalil Alves de Lima,Cristina Gutiérrez-Vázquez,Patrick Hewson,Ori Staszewski,Manon Blain,Luke M. Healy,Tradite Neziraj,Matilde Borio,Michael A. Wheeler,Loic Lionel Dragin,David Laplaud,Jack P. Antel,Jorge I. Alvarez,Marco Prinz,Francisco J. Quintana,Francisco J. Quintana +21 more
TL;DR: It is reported that TGFα and VEGF-B produced by microglia regulate the pathogenic activities of astrocytes in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis, and this pathway may guide new therapies for multiple sclerosis and other neurological disorders.
Journal ArticleDOI
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray,J. Yaouanq,Emmanuelle Le Page,M. Coustans,David Laplaud,Joel Oger,Gilles Edan,Gilles Edan +7 more
TL;DR: The results indicated that the disability progression during Phase 2 was independent of that during Phase 1, demonstrating that multiple sclerosis disability progression follows a two-stage process, with a first stage probably dependant on focal inflammation and a second stage probably independent of current focal inflammation.
Journal ArticleDOI
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
Céline Louapre,Nicolas Collongues,B. Stankoff,C. Giannesini,Caroline Papeix,C. Bensa,Romain Deschamps,Alain Créange,Abir Wahab,Jean Pelletier,Olivier Heinzlef,Pierre Labauge,Laurent Guilloton,Guido Ahle,Mathilde Goudot,Kévin Bigaut,David Laplaud,Sandra Vukusic,Catherine Lubetzki,Jérôme De Seze +19 more
TL;DR: In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and CO VID-19 severity.
Journal ArticleDOI
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
Alvaro Cobo-Calvo,Anne Ruiz,Elisabeth Maillart,Bertrand Audoin,Hélène Zéphir,Bertrand Bourre,Jonathan Ciron,Nicolas Collongues,David Brassat,François Cotton,Caroline Papeix,Françoise Durand-Dubief,David Laplaud,Romain Deschamps,Mikael Cohen,Damien Biotti,Xavier Ayrignac,Caroline Tilikete,Eric Thouvenot,Bruno Brochet,Cécile Dulau,Thibault Moreau,Ayman Tourbah,Pierre Lebranchu,Laure Michel,Christine Lebrun-Frenay,Alexis Montcuquet,Guillaume Mathey,Marc Debouverie,Jean Pelletier,Pierre Labauge,Nathalie Derache,M. Coustans,Fabien Rollot,Jérôme De Seze,Sandra Vukusic,Romain Marignier +36 more
TL;DR: In adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord and despite the relapsing course, the overall visual and motor outcome is better compared with AQP4- Ab-positive patients.
Journal ArticleDOI
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Jérôme De Seze,Marc Debouverie,Hélène Zéphir,Christine Lebrun,Frédéric Blanc,Véronique Bourg,Sandrine Wiertlewski,Sophie Pittion,David Laplaud,Emmanuelle Le Page,Romain Deschamps,Philippe Cabre,Jean Pelletier,Irina Malikova,Pierre Clavelou,Valérie Jaillon,Gilles Defer,Pierre Labauge,Olivier Gout,Clotilde Boulay,Gilles Edan,Patrick Vermersch +21 more
TL;DR: This study found some differences concerning the risk of evolution to clinically definite MS after a first demyelinating episode suggestive of ADEM, and proposed criteria that should now be tested in a larger, prospective cohort study.